Buy­out buzz: Is As­traZeneca hunt­ing a mi­cro-M&A deal on Nas­daq?

A cou­ple of weeks af­ter be­ing told by the pow­ers that be at Nas­daq that it will need to get its bat­tered share price out of pen­ny stock ter­ri­to­ry if it wants to keep its list­ing, Mereo Bio­Phar­ma has picked up some steam to­day with the ru­mor that As­traZeneca has come call­ing to see about an ac­qui­si­tion.

If it’s ac­cu­rate, As­traZeneca — which has de­vel­oped in­to a pow­er­house on­col­o­gy play­er with a very se­lect ap­petite for high-dol­lar deals — is shop­ping the bar­gain base­ment on Wall Street af­ter the biotech bear mar­ket evis­cer­at­ed Mereo’s mar­ket cap.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER